AUGUSTUS
An open-label, 2 x 2 factorial, randomized controlled, clinical trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspririn vs. aspririn placebo in patients with atrial fibrillation and ACS or PCI
- Stadium
- klaar
- Middel
- apixaban
- Populatie
- ASCVD
- Fase
- IV
- First Patient In
- 1 oktober 2017
- Last Patient In
- 10 april 2018
- Last Patient Last Visit
- 12 oktober 2018
National Lead
dr. A.M.W. Alings
Cardioloog
Studiedirecteur
